Skip to main content

Animations

Funded Studies

The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.

Search or browse funded studies

Previously funded studies appear chronologically, with the most recent appearing first.

Filters
From
To
  • ${value}

Filter Results (2655${count})

  • Therapeutic Pipeline Program, 2016
    Highly Selective M1 Muscarinic Receptor Positive Allosteric Modulators for the Treatment of Parkinson's Dementia

    Study Rationale:                             
    Up to 80% of individuals with Parkinson’s develop Parkinson’s disease dementia (PDD), which is characterized by a progressive loss of memory and a decline...

  • Therapeutic Pipeline Program, 2015
    Alpha4Beta2 Nicotinic Agonist for Treatment of L-Dopa Refractory Gait and Balance Disorders in Parkinson Disease

    Study Rationale:
    Gait and balance problems, particularly falls, are common and disabling symptoms in Parkinson disease (PD), and do not improve markedly with existing treatments. Studies have indicated...

  • Target Advancement Program, 2016
    Genetic Modulation of LAMP-2A in PD Models

    Study Rationale:                   
    Brain cells use surveillance mechanisms to get rid of toxic proteins, such as mutant alpha-synuclein, that otherwise would accumulate and kill them. We have...

  • Target Advancement Program, 2016
    Mechanism of TFEB Dysfunction by GBA1 Mutation in Human iPSC-derived Dopaminergic Neurons

    Study Rationale:
    People who have mutations in the GBA1 gene have a higher chance of developing Parkinson's disease (PD) but it is unclear why. We found that GBA1 mutations affect the cellular ability...

  • Target Validation, 2015
    Validating the Neuroprotective Enzyme ACMSD as a Novel Therapeutic Target in Parkinson's Disease by Viral Vector-Mediated Overexpression

    Study Rationale:                             
    A number of genetic studies have linked variation in the enzyme aminocarboxy-muconate semialdehyde decarboxylase (ACMSD) with a risk for Parkinson’s...

  • Target Validation, 2013
    IL-13Ra1 and Neuroinflammatory Damage in the MPTP Pre-Clinical Model of PD

    Study Rationale:                   
    Neuroinflammation has been proposed to contribute to both the pathogenesis and the progression of Parkinson's disease (PD). We recently showed that an important...

Two female doctors talking in the lab.

Apply for a Grant

Our funding programs support basic, translational and clinical research from academia and industry.

See Funding Opportunities
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.